Arcus Biosciences Announces Participation at Upcoming Investor Conference

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced that Terry Rosen, Ph.D., Chief Executive Officer, will
participate in a fireside chat at the 8th Annual Leerink
Partners Global Healthcare Conference on Wednesday, February 27, 2019 at
11:30 am ET at the Lotte New York Palace, in New York, NY.

To access the live audio webcast of the presentation, please visit the
“Events & Presentations” section of the Arcus website at
A replay of the webcast will be available for 30 days following the live

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is in a Phase 1/1b program to
evaluate AB928 in combination with other agents in multiple tumor types,
and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1
trial and is being tested in combination with Arcus’s other product
candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive
in-house expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about Arcus
Biosciences, please visit


Nicole Arndt
(510) 284-4728

error: Content is protected !!